- Home
- INSM
INSM
Insmed Incorporated
as 06-20-2025 4:00pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 17.3B | IPO Year: | 2000 |
| Target Price: | $106.80 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $102.70 | Next Earning Date: | 08-07-2025 |
| Revenue: | $381,030,000 | Revenue Growth: | 20.77% |
| Revenue Growth (this year): | 28.03% | Revenue Growth (next year): | 120.54% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jun 10 '25 | Sell | $91.57 | 45,163 | $4,117,067.10 | 83,111 | |
| Bonstein Sara | INSM | Chief Financial Officer | Jun 10 '25 | Sell | $89.47 | 57,766 | $5,148,024.17 | 146,591 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Jun 5 '25 | Sell | $73.50 | 1,879 | $138,106.50 | 67,718 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Jun 3 '25 | Sell | $71.50 | 1,686 | $120,549.00 | 83,111 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Jun 3 '25 | Sell | $71.50 | 1,642 | $117,403.00 | 118,579 | |
| Bonstein Sara | INSM | Chief Financial Officer | Jun 3 '25 | Sell | $71.50 | 1,579 | $112,898.50 | 146,591 | |
| Adsett Roger | INSM | Chief Operating Officer | Jun 3 '25 | Sell | $71.50 | 1,860 | $132,990.00 | 141,323 | |
| MCGIRR DAVID W J | INSM | Director | Jun 3 '25 | Sell | $72.29 | 6,250 | $451,535.00 | 97,723 | |
| Lewis William | INSM | Chair and CEO | Jun 2 '25 | Sell | $71.26 | 12,302 | $878,292.20 | 233,924 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | May 30 '25 | Sell | $69.28 | 26,327 | $1,833,779.12 | 67,718 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insider Monkey
4 days ago
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107
Insider Monkey
4 days ago
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating
Insider Monkey
8 days ago
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
BioPharma Dive
8 days ago
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
Insider Monkey
9 days ago
Insmed (INSM) Soars After Raising $650 million
Insider Monkey
9 days ago
Insmed Inc (INSM) Soars 30% on Impressive Study
MT Newswires
9 days ago
Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.